Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 5;21(3):1061.
doi: 10.3390/ijms21031061.

Defeating Antibiotic-Resistant Bacteria: Exploring Alternative Therapies for a Post-Antibiotic Era

Affiliations
Review

Defeating Antibiotic-Resistant Bacteria: Exploring Alternative Therapies for a Post-Antibiotic Era

Chih-Hung Wang et al. Int J Mol Sci. .

Abstract

Antibiotics are one of the greatest medical advances of the 20th century, however, they are quickly becoming useless due to antibiotic resistance that has been augmented by poor antibiotic stewardship and a void in novel antibiotic discovery. Few novel classes of antibiotics have been discovered since 1960, and the pipeline of antibiotics under development is limited. We therefore are heading for a post-antibiotic era in which common infections become untreatable and once again deadly. There is thus an emergent need for both novel classes of antibiotics and novel approaches to treatment, including the repurposing of existing drugs or preclinical compounds and expanded implementation of combination therapies. In this review, we highlight to utilize alternative drug targets/therapies such as combinational therapy, anti-regulator, anti-signal transduction, anti-virulence, anti-toxin, engineered bacteriophages, and microbiome, to defeat antibiotic-resistant bacteria.

Keywords: alternative therapies; antibiotic resistance; regulator; signal transduction; virulence factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Illustration of alternative antibacterial therapies: (A) increase membrane permeability, (B) inhibit kinase activity and intrinsic resistance, (C) anti-regulators, (D) anti-quorum sensing system, (E) reduce adhesion and motility, and (F) anti-toxins and secretion system.

References

    1. Cizman M., Plankar Srovin T. Antibiotic consumption and resistance of gram-negative pathogens (collateral damage) GMS Infect. Dis. 2018;6:Doc05. - PMC - PubMed
    1. Woolhouse M., Waugh C., Perry M.R., Nair H. Global disease burden due to antibiotic resistance - state of the evidence. J. Glob. Health. 2016;6:010306. doi: 10.7189/jogh.06.010306. - DOI - PMC - PubMed
    1. Zhen X., Lundborg C.S., Sun X., Hu X., Dong H. Economic burden of antibiotic resistance in ESKAPE organisms: A systematic review. Antimicrob. Resist. Infect. Control. 2019;8:137. doi: 10.1186/s13756-019-0590-7. - DOI - PMC - PubMed
    1. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J. Infect. Dis. 2008;197:1079–1081. doi: 10.1086/533452. - DOI - PubMed
    1. Marturano J.E., Lowery T.J. ESKAPE Pathogens in Bloodstream Infections Are Associated With Higher Cost and Mortality but Can Be Predicted Using Diagnoses Upon Admission. Open Forum Infect. Dis. 2019;6:ofz503. doi: 10.1093/ofid/ofz503. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources